NeuroPace (NPCE) Income from Continuing Operations (2020 - 2026)
NeuroPace's (NPCE) quarterly Income from Continuing Operations came in at 21967000.0 in Q1 2026, down 235.17% year-on-year from 16251463.82 in Q1 2025, and down 470.42% quarter-over-quarter from 3851000.0 in Q4 2025.
NeuroPace (NPCE) Income from Continuing Operations (2020 - 2026) Analysis & Trends
NeuroPace's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 21967000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 235.17% year-over-year to 21967000.0 in Q1 2026; TTM through Mar 2026 was 52765000.0, a 110.36% decrease from a year earlier, with the FY2025 full-year figure at 36032000.0, up 62.79% from the prior year.
- Income from Continuing Operations slipped to 21967000.0 in Q1 2026 per NPCE's latest filing, from 3851000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 3851000.0 in Q4 2025 and bottomed at 21967000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 9018000.0 (2024), against an average of 9777411.76.
- Across the five-year window, Income from Continuing Operations jumped 41.55% in 2023 and plunged 235.17% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 11000000.0 in 2022, then soared by 41.55% to 6429000.0 in 2023, then grew by 19.55% to 5172000.0 in 2024, then advanced by 25.54% to 3851000.0 in 2025, then plunged by 470.42% to 21967000.0 in 2026.
- Per Business Quant, the three latest NPCE Income from Continuing Operations figures stand at 21967000.0 (Q1 2026), 3851000.0 (Q4 2025), and 4985000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | NeuroPace | 494.96 Mn | 440.98 Mn | 18.05 Mn | -21.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.97 Mn |
| Dec 31, 2025 | -3.85 Mn |
| Sep 30, 2025 | -4.99 Mn |
| Jun 30, 2025 | -21.96 Mn |
| Mar 31, 2025 | -6.55 Mn |
| Dec 31, 2024 | -5.17 Mn |
| Sep 30, 2024 | -5.69 Mn |
| Jun 30, 2024 | -7.67 Mn |
| Mar 31, 2024 | -9.02 Mn |
| Dec 31, 2023 | -6.43 Mn |
| Sep 30, 2023 | -7.37 Mn |
| Jun 30, 2023 | -9.25 Mn |
| Mar 31, 2023 | -9.56 Mn |
| Dec 31, 2022 | -11.00 Mn |
| Sep 30, 2022 | -11.68 Mn |
| Jun 30, 2022 | -12.61 Mn |
| Mar 31, 2022 | -11.46 Mn |
| Dec 31, 2021 | -11.50 Mn |
| Sep 30, 2021 | -7.93 Mn |
| Jun 30, 2021 | -6.38 Mn |